Patents by Inventor MARTIN BERNARD CATHERINE BOUSMANNE

MARTIN BERNARD CATHERINE BOUSMANNE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240109841
    Abstract: This disclosure describes compounds of Formula (I), stereoisomers, side compounds thereof, pharmaceutical compositions and methods of manufacturing such compounds, using silylation reagents and producing compositions and products made using such methods. More particularly, this disclosure describes manufacture of trofinetide and side products, compositions and products containing such compounds, for pharmaceutical uses to treat neurodegenerative or neurodevelopmental disorders.
    Type: Application
    Filed: November 21, 2023
    Publication date: April 4, 2024
    Inventors: Clive BLOWER, Matthew PETERSON, James Murray SHAW, James Anthony BONNAR, Etienne David Frank Philippe MONIOTTE, Martin Bernard Catherine BOUSMANNE, Cecilia BETTI, Karel Willy Luc DECROOS, Mimoun AYOUB
  • Patent number: 11866406
    Abstract: This disclosure describes compounds of Formula (I), stereoisomers, side compounds thereof, pharmaceutical compositions and methods of manufacturing such compounds, using silylation reagents and producing compositions and products made using such methods. More particularly, this disclosure describes manufacture of trofinetide and side products, compositions and products containing such compounds, for pharmaceutical uses to treat neurodegenerative or neurodevelopmental disorders.
    Type: Grant
    Filed: June 23, 2022
    Date of Patent: January 9, 2024
    Assignee: NEUREN PHARMACEUTICALS LIMITED
    Inventors: Clive Blower, Mathew Peterson, James Murray Shaw, James Anthony Bonnar, Etienne David Frank Philippe Moniotte, Martin Bernard Catherine Bousmanne, Cecilia Betti, Karel Willy Luc Decroos, Mimoun Ayoub
  • Patent number: 11827600
    Abstract: This disclosure provides crystalline forms of trofinetide and trofinetide hydrate, pharmaceutical compositions comprising crystalline forms of trofinetide and trofinetide hydrate, methods of making crystalline forms of trofinetide or trofinetide hydrate, and methods of treating a disease, condition, or disorder in a subject comprising administering a composition comprising crystalline forms of trofinetide or trofinetide hydrate to the subject.
    Type: Grant
    Filed: July 12, 2022
    Date of Patent: November 28, 2023
    Assignee: Acadia Pharmaceuticals Inc.
    Inventors: Matthew Peterson, Marlon Carlos, Martin Bernard Catherine Bousmanne, Cecilia Betti, David T. Jonaitis, Lisa M. McCracken, Lisa M. Grove
  • Publication number: 20230023114
    Abstract: This disclosure provides crystalline forms of trofinetide and trofinetide hydrate, pharmaceutical compositions comprising crystalline forms of trofinetide and trofinetide hydrate, methods of making crystalline forms of trofinetide or trofinetide hydrate, and methods of treating a disease, condition, or disorder in a subject comprising administering a composition comprising crystalline forms of trofinetide or trofinetide hydrate to the subject.
    Type: Application
    Filed: July 12, 2022
    Publication date: January 26, 2023
    Inventors: Matthew PETERSON, Marlon CARLOS, Martin Bernard Catherine BOUSMANNE, Cecilia BETTI, David T. JONAITIS, Lisa M. MCCRACKEN, Lisa M. GROVE
  • Publication number: 20220324799
    Abstract: This disclosure describes compounds of Formula (I), stereoisomers, side compounds thereof, pharmaceutical compositions and methods of manufacturing such compounds, using silylation reagents and producing compositions and products made using such methods. More particularly, this disclosure describes manufacture of trofinetide and side products, compositions and products containing such compounds, for pharmaceutical uses to treat neurodegenerative or neurodevelopmental disorders.
    Type: Application
    Filed: June 23, 2022
    Publication date: October 13, 2022
    Inventors: CLIVE BLOWER, MATHEW PETERSON, JAMES MURRAY SHAW, JAMES ANTHONY BONNAR, ETIENNE DAVID FRANK PHILIPPE MONIOTTE, MARTIN BERNARD CATHERINE BOUSMANNE, CECILIA BETTI, KAREL WILLY LUC DECROOS, MIMOUN AYOUB
  • Patent number: 11370755
    Abstract: This disclosure describes compounds of Formula (I), stereoisomers, side compounds thereof, pharmaceutical compositions and methods of manufacturing such compounds, using silylation reagents and producing compositions and products made using such methods. More particularly, this disclosure describes manufacture of trofinetide and side products, compositions and products containing such compounds, for pharmaceutical uses to treat neurodegenerative or neurodevelopmental disorders.
    Type: Grant
    Filed: June 14, 2021
    Date of Patent: June 28, 2022
    Assignee: NEUREN PHARMACEUTICALS LIMITED
    Inventors: Clive Blower, Mathew Peterson, James Murray Shaw, James Anthony Bonnar, Etienne David Frank Philippe Moniotte, Martin Bernard Catherine Bousmanne, Cecilia Betti, Karel Willy Luc Decroos, Mimoun Ayoub
  • Publication number: 20220055987
    Abstract: This disclosure describes compounds of Formula (I), stereoisomers, side compounds thereof, pharmaceutical compositions and methods of manufacturing such compounds, using silylation reagents and producing compositions and products made using such methods. More particularly, this disclosure describes manufacture of trofinetide and side products, compositions and products containing such compounds, for pharmaceutical uses to treat neurodegenerative or neurodevelopmental disorders.
    Type: Application
    Filed: June 14, 2021
    Publication date: February 24, 2022
    Inventors: CLIVE BLOWER, MATHEW PETERSON, JAMES MURRAY SHAW, JAMES ANTHONY BONNAR, ETIENNE DAVID FRANK PHILIPPE MONIOTTE, MARTIN BERNARD CATHERINE BOUSMANNE, CECILIA BETTI, KAREL WILLY LUC DECROOS, MIMOUN AYOUB